Trial reportBlood2019
Molecular remission and response patterns in patients with mutant-
2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 181 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 2 pooled it
30.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Precision Therapy Versus Standard Therapy in Acute Myeloid Leukaemia and Myelodysplastic Syndrome in Elderly
Who cites it
181 citing papers in PubMed, 2 syntheses or guidelines pooled it, 323 citations in OpenAlex.
- Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.Clinical epigenetics · 2023Pooled it
- Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.Frontiers in oncology · 2020Pooled it
- Trial
- Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Blood cancer journal · 2022Trial
- Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.Cancer medicine · 2020Trial
- Trial
- Defining and managing high-risk acute myeloid leukemia (AML) in 2026.Annals of hematology · 2026Review
- Targeting mitochondrial TRIP13-AIF interaction suppresses myeloid leukemia progression and overcomes drug resistance.Oncogene · 2026Article
- Identification and Management of Differentiation Syndrome in Emergency Settings: A Narrative Review.Cancers · 2026Review
- Review
- Advancements in targeted therapies for acute myeloid leukemia.Current opinion in pharmacology · 2026Review
- Cancer Metabolism and Its Historical & Molecular Foundations: An Overview.Drugs and drug candidates · 2026Article
- Epigenetic Targeting in Myeloid Malignancies.Advances in experimental medicine and biology · 2026Review
- Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia.Blood and lymphatic cancer : targets and therapy · 2026Review
- Concurrent therapy-related acute myeloid leukemia and lymph node tuberculosis following treatment for lung squamous cell carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients.Blood · 2025Article
- Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.Annals of hematology · 2025Article
- Analytical Performance of the NCI-myeloMATCH Assay: A Rapid Turnaround Genomic Profiling Assay for Myeloid Disorders.The Journal of molecular diagnostics : JMD · 2025Article
- Prevalence of IDH1/IDH2 Mutations in Adult Indian Acute Myeloid Leukaemia Patients and Their Impact on Outcome.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Abnormal changes in metabolites caused by mJournal of advanced research · 2025Review
121 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 16 institutions in 4 countries.
Eytan M SteinMemorial Sloan Kettering Cancer Center, New York, NY.
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center, Houston, TX.
Amir T FathiMassachusetts General Hospital Cancer Center, Boston, MA.
Daniel A PollyeaUniversity of Colorado School of Medicine, Aurora, CO.
Richard M StoneDana-Farber Cancer Institute, Boston, MA.
Jessica K AltmanRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Gail J RobozWeill Cornell Medical College, New York, NY.
Manish R PatelFlorida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL.
Robert CollinsUniversity of Texas Southwestern Medical Center, Dallas, TX.
Ian W FlinnSarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
Mikkael A SekeresCleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Anthony S SteinGehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
Hagop M KantarjianThe University of Texas MD Anderson Cancer Center, Houston, TX.
Ross L LevineMemorial Sloan Kettering Cancer Center, New York, NY.
Paresh VyasMRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom.
Kyle J MacBethCelgene Corporation, San Francisco, CA.
Alessandra TosoliniCelgene Corporation, Summit, NJ.
Jason VanOostendorpCelgene Corporation, Summit, NJ.
Qiang XuCelgene Corporation, Summit, NJ.
Ira GuptaCelgene Corporation, Summit, NJ.
Thomas LilaCelgene Corporation, San Francisco, CA.
Alberto RisuenoCelgene Institute for Translational Research Europe, Seville, Spain.
Katharine E YenAgios Pharmaceuticals, Inc., Cambridge, MA.
Bin WuAgios Pharmaceuticals, Inc., Cambridge, MA.
Eyal C AttarAgios Pharmaceuticals, Inc., Cambridge, MA.
Martin S TallmanMemorial Sloan Kettering Cancer Center, New York, NY.
Stéphane de BottonGustave Roussy, Département d'hématologie et Département d'innovation thérapeutique, Villejuif, France; and.
Agios Pharmaceuticals (United States) · USMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USCity of Hope · USCleveland Clinic · USDana-Farber Cancer Institute · USInstituto de Investigaciones Químicas · ESMassachusetts General Hospital · USNewYork–Presbyterian Hospital · USNorthwestern University · USOxford BioMedica (United Kingdom) · GBSarah Cannon · USTennessee Oncology · USThe University of Texas Southwestern Medical Center · USUniversité Paris-Saclay · FRUniversity of Colorado Denver · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MMedical Research Council G1000729Medical Research Council MC_U137961146Medical Research Council MC_UU_00016/11Medical Research Council MC_UU_12009/11Medical Research Council MR/L008963/1NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672
Abstract
Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (
Indexed as
MutationAdultAgedAged, 80 and overAminopyridinesBiomarkers, TumorFemaleFollow-Up StudiesHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMiddle AgedMutant ProteinsNeoplasm Recurrence, LocalPrognosisAminopyridinesBiomarkers, TumorenasidenibIDH2 protein, humanIsocitrate DehydrogenaseMutant ProteinsTriazines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01915498ClinicalTrials.gov
NCT05025098ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.